Drugs / 4- [F-18] fluoropaclitaxel
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT00572598 | May 2005 → Mar 2008 | breast cancer | Virginia Commonwealth University | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 4- [F-18] fluoropaclitaxel | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00572598 ↗ |
| Known as | FPAC | “FPAC” NCT00572598 ↗ |
| Modality | Diagnostic / imaging agent | “4-[18F]Fluoropaclitaxel (FPAC) is a PET-radiolabeled analogue of paclitaxel.” PMID 17921033 ↗ Jul 2007 |
| Route | Intravenous | “received an intravenous infusion of (18)F-fluoropaclitaxel and then underwent PET/CT” PMID 21849404 ↗ Aug 2011 |